288 filings
Page 5 of 15
8-K
idvk z62f01y
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
ni35j
28 May 20
Departure of Directors or Certain Officers
4:16pm
DEFA14A
0i3s62m9
13 May 20
Additional proxy soliciting materials
4:31pm
8-K
aauga8g9hut9wzd0jk
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
DEFA14A
bm63 zykh0tec4j
9 Apr 20
Additional proxy soliciting materials
4:05pm
8-K
1fcfozmemk27jx545t
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
S-8
8qvcrs92
2 Mar 20
Registration of securities for employees
4:39pm
8-K
35k96d4vzvkkn
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
fye8zdanz41n7r
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
424B5
poects7djtua98dq d9
8 Jan 20
Prospectus supplement for primary offering
5:06pm
8-K
xuyvdr lwxna
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
892gw9 u2bli
6 Jan 20
Prospectus supplement for primary offering
4:42pm
S-3ASR
o6bxs1zcm8xt0hhup5x
6 Jan 20
Automatic shelf registration
4:02pm
8-K
fzykhgm673
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
jbr83 escs721szoxe
5 Nov 19
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
7:40am
EFFECT
e6kyp4sla8t8
13 Sep 19
Notice of effectiveness
12:15am